These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38803182)

  • 1. Plasma Biomarkers in Neurodegenerative Dementias: Unrevealing the Potential of Serum Oxytocin, BDNF, NPTX1, TREM2, TNF-alpha, IL-1 and Prolactin.
    Olğun Y; Poyraz CA; Bozluolçay M; Konukoğlu D; Poyraz BÇ
    Curr Alzheimer Res; 2024; 21(2):109-119. PubMed ID: 38803182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative EEG in the Differential Diagnosis of Dementia Subtypes.
    Olğun Y; Aksoy Poyraz C; Bozluolçay M; Poyraz BÇ
    J Geriatr Psychiatry Neurol; 2024 Sep; 37(5):368-378. PubMed ID: 38217438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma biomarkers of amyloid, tau, axonal, and neuroinflammation pathologies in dementia with Lewy bodies.
    Vrillon A; Bousiges O; Götze K; Demuynck C; Muller C; Ravier A; Schorr B; Philippi N; Hourregue C; Cognat E; Dumurgier J; Lilamand M; Cretin B; Blanc F; Paquet C
    Alzheimers Res Ther; 2024 Jul; 16(1):146. PubMed ID: 38961441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoantibodies against amyloid and glial-derived antigens are increased in serum and cerebrospinal fluid of Lewy body-associated dementias.
    Maetzler W; Berg D; Synofzik M; Brockmann K; Godau J; Melms A; Gasser T; Hörnig S; Langkamp M
    J Alzheimers Dis; 2011; 26(1):171-9. PubMed ID: 21593566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel fluid biomarkers to differentiate frontotemporal dementia and dementia with Lewy bodies from Alzheimer's disease: A systematic review.
    Chaudhry A; Houlden H; Rizig M
    J Neurol Sci; 2020 Aug; 415():116886. PubMed ID: 32428759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    Chouliaras L; Thomas A; Malpetti M; Donaghy P; Kane J; Mak E; Savulich G; Prats-Sedano MA; Heslegrave AJ; Zetterberg H; Su L; Rowe JB; O'Brien JT
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):651-658. PubMed ID: 35078917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Search in the Periphery for Potential Inflammatory Biomarkers of Dementia with Lewy Bodies and Alzheimer's Disease.
    Costantini E; Carrarini C; Calisi D; De Rosa M; Simone M; Di Crosta A; Palumbo R; Cipollone A; Aielli L; De Laurentis M; Colarusso L; Pilotto A; Padovani A; Konstantinidou F; Gatta V; Stuppia L; Cipollone F; Di Nicola M; Reale M; Bonanni L
    J Alzheimers Dis; 2024; 99(3):1147-1158. PubMed ID: 38759010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BDNF serum concentrations show no relationship with diagnostic group or medication status in neurodegenerative disease.
    Woolley JD; Strobl EV; Shelly WB; Karydas AM; Robin Ketelle RN; Wolkowitz OM; Miller BL; Rankin KP
    Curr Alzheimer Res; 2012 Sep; 9(7):815-21. PubMed ID: 21605064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum brain-derived neurotrophic factor levels in different neurological diseases.
    Ventriglia M; Zanardini R; Bonomini C; Zanetti O; Volpe D; Pasqualetti P; Gennarelli M; Bocchio-Chiavetto L
    Biomed Res Int; 2013; 2013():901082. PubMed ID: 24024214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma YKL-40 in the spectrum of neurodegenerative dementia.
    Villar-Piqué A; Schmitz M; Hermann P; Goebel S; Bunck T; Varges D; Ferrer I; Riggert J; Llorens F; Zerr I
    J Neuroinflammation; 2019 Jul; 16(1):145. PubMed ID: 31299989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias.
    Herbert MK; Aerts MB; Kuiperij HB; Claassen JAHR; Spies PE; Esselink RAJ; Bloem BR; Verbeek MM
    Alzheimers Dement; 2014 Jul; 10(4):448-455.e2. PubMed ID: 24239248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies.
    Binnewijzend MA; Kuijer JP; van der Flier WM; Benedictus MR; Möller CM; Pijnenburg YA; Lemstra AW; Prins ND; Wattjes MP; van Berckel BN; Scheltens P; Barkhof F
    Eur Radiol; 2014 Sep; 24(9):2326-33. PubMed ID: 24996793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Combination of Neurofilament Light, Glial Fibrillary Acidic Protein, and Neuronal Pentraxin-2 Discriminates Between Frontotemporal Dementia and Other Dementias.
    Bolsewig K; Hok-A-Hin YS; Sepe FN; Boonkamp L; Jacobs D; Bellomo G; Paoletti FP; Vanmechelen E; Teunissen CE; Parnetti L; Willemse EAJ
    J Alzheimers Dis; 2022; 90(1):363-380. PubMed ID: 36120776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
    Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
    Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Matrix Metalloproteinase-2 (MMP-2) and -9 (MMP-9) and Their Tissue Inhibitors (TIMP-1 and TIMP-2) in Plasma from Patients with Neurodegenerative Dementia.
    Tuna G; Yener GG; Oktay G; İşlekel GH; Kİrkalİ FG
    J Alzheimers Dis; 2018; 66(3):1265-1273. PubMed ID: 30412498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of QOL between patients with different degenerative dementias, focusing especially on positive and negative affect.
    Kurisu K; Terada S; Oshima E; Horiuchi M; Imai N; Yabe M; Yokota O; Ishihara T; Yamada N
    Int Psychogeriatr; 2016 Aug; 28(8):1355-61. PubMed ID: 27020694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebrospinal Fluid/Plasma Albumin Ratio as a Biomarker for Blood-Brain Barrier Impairment Across Neurodegenerative Dementias.
    Musaeus CS; Gleerup HS; Høgh P; Waldemar G; Hasselbalch SG; Simonsen AH
    J Alzheimers Dis; 2020; 75(2):429-436. PubMed ID: 32280104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.
    Alcolea D; Delaby C; Muñoz L; Torres S; Estellés T; Zhu N; Barroeta I; Carmona-Iragui M; Illán-Gala I; Santos-Santos MÁ; Altuna M; Sala I; Sánchez-Saudinós MB; Videla L; Valldeneu S; Subirana A; Pegueroles J; Hirtz C; Vialaret J; Lehmann S; Karikari TK; Ashton NJ; Blennow K; Zetterberg H; Belbin O; Blesa R; Clarimón J; Fortea J; Lleó A
    J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1206-1214. PubMed ID: 34103344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.